Salih Zeki Güçlü

Afatinib versus erlotinib as second-line treatment of patients with advanced squamous cell carcinoma of the lung (LUX-Lung 8): an open-label randomised controlled phase 3 trial

Jean‐Charles Soria, Enriqueta Felip, Manuel Cobo et al. · The Lancet Oncology · 2015 · 434 citations

Medicine, Oncology, Pharmacology +9

Safety and tolerability of NVA237, a once-daily long-acting muscarinic antagonist, in COPD patients

Claus Vogelmeier, C. Verkindre, D. Cheung et al. · Pulmonary Pharmacology & Therapeutics · 2010 · 57 citations

Medicine, Pharmacology, Pharmacotherapy +13

The impact of active and former smoking on the severity of obstructive sleep apnea

Yelda Varol, Ceyda Anar, Özlem Egemen Tüzel et al. · Sleep And Breathing · 2015 · 54 citations

Medicine, Internal Medicine, Pulmonology +12

Association of <i>ERBB</i> Mutations With Clinical Outcomes of Afatinib- or Erlotinib-Treated Patients With Lung Squamous Cell Carcinoma

Glenwood Goss, Enriqueta Felip, Manuel Cobo et al. · JAMA Oncology · 2018 · 54 citations · Full text

Medicine, Molecular Genetics, Oncology +17

Effectiveness of transbronchial needle aspiration in the diagnosis of exophytic endobronchial lesions and submucosal/peribronchial diseases of the lung

Nazan Kaçar, Fevziye Tuksavul, Özlem Edipoğlu et al. · Lung Cancer · 2005 · 40 citations

Medicine, Pathology, Pulmonology +10